GlassScriptPhysician profile
Elizabeth Lynch
NPI 1730763012
$2,825.15
in general payments reported to CMS, 2019-2025
20 companies · $296 in 2025
The $296 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $167 · 2022: $954 · 2023: $682 · 2024: $726 · 2025: $296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,704.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,704.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,069.63 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $365.43 | 2021-2024 | Trulance |
| Janssen Scientific Affairs, LLC | $205.64 | 2023-2024 | Tremfya, Stelara |
| Genzyme Corporation | $184.61 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $175.42 | 2021-2024 | Entyvio |
| Redhill Biopharma INC. | $165.73 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $149.64 | 2022-2024 | Dupixent |
| Phathom Pharmaceuticals, INC. | $124.86 | 2025 | Voquezna |
| Celgene Corporation | $97.15 | 2022-2024 | Zeposia |
| Janssen Biotech, INC. | $58.89 | 2024-2025 | Stelara, Tremfya |
| Ipsen Biopharmaceuticals, INC | $38.97 | 2024-2025 | Iqirvo |
| Ardelyx, INC. | $32.24 | 2025 | Ibsrela |
| Olympus America INC. | $28.38 | 2023-2024 | Evis Exera III Colonovideoscope |
| Madrigal Pharmaceuticals | $24.32 | 2024 | Resmetirom |
| Ferring Pharmaceuticals INC. | $22.77 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $20.07 | 2025 | Wegovy |
| Celltrion USA INC. | $16.26 | 2025 | Vegzelma |
| Lilly USA, LLC | $15.54 | 2023 | |
| Intercept Pharmaceuticals, INC. | $15.03 | 2021 | |
| Nestle Healthcare Nutrition INC. | $14.57 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Lynch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.